Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients
Open accessThe DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
BACKGROUND: TGF-β has potent profibrotic activity in vitro and has long been implicated in systemic sclerosis (SSc), as expression of TGF-β-regulated genes is increased in the skin and lungs of patients with SSc. Therefore, inhibition of TGF-β may benefit these patients. METHODS: Patients with early, diffuse cutaneous SSc were enrolled in an open-label trial of fresolimumab, a high-affinity neutralizing antibody that targets all 3 TGF-β isoforms. Seven patients received two 1 mg/kg doses of fresolimumab, and eight patients received one 5 mg/kg dose of fresolimumab. Serial mid-forearm skin biopsies, performed before and after treatment, were analyzed for expression of the TGF-β-regulated biomarker genes thrombospondin-1 (THBS1) and cartilage oligomeric protein (COMP) and stained for myofibroblasts. Clinical skin disease was assessed using the modified Rodnan skin score (MRSS). RESULTS: In patient skin, THBS1 expression rapidly declined after fresolimumab treatment in both groups (P = 0.0313 at 7 weeks and P = 0.0156 at 3 weeks), and skin expression of COMP exhibited a strong downward trend in both groups. Clinical skin disease dramatically and rapidly decreased (P < 0.001 at all time points). Expression levels of other TGF-β-regulated genes, including SERPINE1 and CTGF, declined (P = 0.049 and P = 0.012, respectively), and a 2-gene, longitudinal pharmacodynamic biomarker of SSc skin disease decreased after fresolimumab treatment (P = 0.0067). Dermal myofibroblast infiltration also declined in patient skin after fresolimumab (P < 0.05). Baseline levels of THBS1 were predictive of reduced THBS1 expression and improved MRSS after fresolimumab treatment. CONCLUSION: The rapid inhibition of TGF-β-regulated gene expression in response to fresolimumab strongly implicates TGF-β in the pathogenesis of fibrosis in SSc. Parallel improvement in the MRSS indicates that fresolimumab rapidly reverses markers of skin fibrosis. TRIAL REGISTRATION: Clinicaltrials.gov NCT01284322.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a small open label single center study, Fresolimumab (180), a high affinity TGFβ inactivating monoclonal antibody was recently tested in SSc patients, and reduced TGFβ dependent gene expression in skin biopsies and improved modified Rodnan skin score (180).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [180]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preliminary criteria for the classification of systemic sclerosis (scleroderma)
Masi, A. T., & Subcommittee For Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230510 · Cited by 4,898
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis
(2001) · Classic Papers in Rheumatology · doi:10.3109/9780203214237-95 · Cited by 3,950
Open source clustering software
de Hoon, M. J. L., Imoto, S., Nolan, J., & Miyano, S. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth078 · Cited by 3,043
Roberts, A. B., Sporn, M. B., Assoian, R. K., Smith, J. M., Roche, N. S., Wakefield, L. M., Heine, U. I., Liotta, L. A., Falanga, V, & Kehrl, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4167 · Cited by 2,866
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Self-citationTransforming growth factor type beta induces monocyte chemotaxis and growth factor production.
Wahl, S. M., Hunt, D. A., Wakefield, L. M., McCartney-Francis, N., Wahl, L. M., Roberts, A. B., & Sporn, M. B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.16.5788 · Cited by 1,272
Systemic sclerosis: a prototypic multisystem fibrotic disorder
Varga, J., & Abraham, D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31139 · Cited by 1,163
Type beta transforming growth factor: a bifunctional regulator of cellular growth.
Roberts, A. B., Anzano, M. A., Wakefield, L. M., Roche, N. S., Stern, D. F., & Sporn, M. B. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.1.119 · Cited by 1,094
Research works printed but not linked: 3
- Derynck R, Miyaono K, eds. The TGF-Beta Family. Cold Spring Harbor Monograph Series 50. Cold Spring Harbor, New York, USA: Cold Spring Harbor Laboratory Press; 2007.
- 10.1002/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q · doi:10.1002/1529-0131(200011)43:11<2445::aid-anr11>3.0.co;2-q
- Rice, Arthritis Rheum.
Cited by
Items 101–200 of 350
Makino, K., Makino, T., Stawski, L., Mantero, J. C., Lafyatis, R., Simms, R. W., & Trojanowska, M. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.03.032 · Cited by 54
Self-citationChung, L. S., Spino, C., McLain, R. W., Johnson, S. R., Denton, C. P., Molitor, J. A., Steen, V. D., Lafyatis, R., Simms, R. W., Kafaja, S., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30237-x · Cited by 51
Self-citationMacrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy
Fendl, B., Berghoff, A. S., Preusser, M., & Maier, B. (2023) · ESMO Open · doi:10.1016/j.esmoop.2022.100776 · Cited by 54
Pathogenesis of systemic sclerosis: an integrative review of recent advances
Son, H.-Y., & Moon, S. (2024) · Journal of Rheumatic Diseases · doi:10.4078/jrd.2024.0129 · Cited by 61
Truchetet, M., Demoures, B., Guimaraes, J. E., Bertrand, A., Laurent, P., Jolivel, V., Douchet, I., Jacquemin, C., Khoryati, L., Duffau, P., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39817 · Cited by 53
Bian, X., Piipponen, M., Liu, Z., Luo, L., Geara, J., Chen, Y., Sangsuwan, T., Maselli, M., Diaz, C., Bain, C. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53295-1 · Cited by 51
Emerging strategies for treatment of systemic sclerosis
Khanna, D., Distler, J. H. W., Sandner, P., & Distler, O. (2016) · Journal of Scleroderma and Related Disorders · doi:10.5301/jsrd.5000207 · Cited by 47
Aberrant TGF-β activation in bone tendon insertion induces enthesopathy-like disease
Wang, X., Xie, L., Crane, J. L., Zhen, G., Li, F., Yang, P., Gao, M., Deng, R., Wang, Y., Jia, X., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96186 · Cited by 76
Azzam, M., Elsafy, S., Abdelgelil, S. A., Weiskirchen, R., Asimakopoulou, A., Lorenzi, F. D., Lammers, T., Mansour, S., & Tammam, S. N. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060590 · Cited by 43
Cell-penetrating peptides selectively targeting SMAD3 inhibit profibrotic TGF-β signaling
Kang, J. H., Jung, M.-Y., Yin, X., Andrianifahanana, M., Hernandez, D. M., & Leof, E. B. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88696 · Cited by 43
Current perspectives on the role of CD8+ T cells in systemic sclerosis
Fuschiotti, P. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.10.002 · Cited by 47
The Roles of TGF-β Signaling in Cerebrovascular Diseases
Zhang, Y., & Yang, X. Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.567682 · Cited by 51
Therapeutic antibodies: A new era in the treatment of respiratory diseases?
Sécher, T., Guilleminault, L., Reckamp, K. L., Amanam, I. U., Plantier, L., & Heuzé‐Vourc'h, N. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.003 · Cited by 45
Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies
Lescoat, A., Roofeh, D., Kuwana, M., Lafyatis, R., Allanore, Y., & Khanna, D. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08891-0 · Cited by 41
Self-citationAdipocyte-specific Repression of PPAR-gamma by NCoR Contributes to Scleroderma Skin Fibrosis
Korman, B. D., Marangoni, R. G., Lord, G., Olefsky, J. M., Tourtellotte, W. G., & Varga, J. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1630-z · Cited by 41
Dendritic cells in systemic sclerosis: Advances from human and mice studies
Affandi, A. J., Carvalheiro, T., Radstake, T. R. D. J., & Marut, W. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.11.003 · Cited by 45
Taki, Z., Gostjeva, E. V., Thilly, W. G., Yaseen, B., Lopez, H., Mirza, M., Hassuji, Z., Vigneswaran, S., Abdi, B. A., Hart, A., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41267 · Cited by 41
Management of Connective Tissue Disease–related Interstitial Lung Disease
Ahmed, S., & Handa, R. (2022) · Current Pulmonology Reports · doi:10.1007/s13665-022-00290-w · Cited by 39
Clinical, mechanistic, and therapeutic landscape of cutaneous fibrosis
Li, D. J., Berry, C. E., Wan, D. C., & Longaker, M. T. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adn7871 · Cited by 45
Delaney, T. A., Morehouse, C., Brohawn, P. Z., Groves, C., Colonna, M., Yao, Y., Sanjuán, M. A. F., & Coyle, A. J. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502190 · Cited by 38
The Communication from Immune Cells to the Fibroblasts in Keloids: Implications for Immunotherapy
Zhang, X., Wu, X., & Li, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015475 · Cited by 46
Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches
Benfaremo, D., Svegliati, S., Paolini, C., Agarbati, S., & Moroncini, G. (2022) · Biomedicines · doi:10.3390/biomedicines10010163 · Cited by 46
Zhu, L., Liu, L., Wang, A., Liu, J., Huang, X., & Zan, T. (2023) · Matrix Biology · doi:10.1016/j.matbio.2023.05.001 · Cited by 42
Regulatory T cells in autoimmune skin diseases
Ujiie, H. (2018) · Experimental Dermatology · doi:10.1111/exd.13535 · Cited by 41
Bon, H., Hales, P., Lumb, S., Holdsworth, G., Johnson, T. S., Qureshi, O. S., & Twomey, B. M. (2019) · The Nephron journals/Nephron journals · doi:10.1159/000499506 · Cited by 39
Upcoming treatments for morphea
Wenzel, D., Haddadi, N., Afshari, K., Richmond, J. M., & Rashighi, M. (2021) · Immunity Inflammation and Disease · doi:10.1002/iid3.475 · Cited by 40
Denton, C. P., Galdo, F. D., Khanna, D., Vonk, M. C., Chung, L. S., Johnson, S. R., Varga, J., Furst, D. E., Temple, J., Zecchin, C., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac300 · Cited by 38
Lei, Z., Teng, Q., Koya, J., Liu, Y., Chen, Z., Zeng, L., Chen, Z., Fang, S., Wang, J., Liu, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1417201 · Cited by 41
An international perspective on the future of systemic sclerosis research
Abraham, D., Black, C. M., Denton, C. P., Distler, J. H. W., Domsic, R. T., Feghali‐Bostwick, C. A., Gourh, P., Hinchcliff, M., Kolling, F., Kuwana, M., et al. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01217-2 · Cited by 43
Self-citationGarcía‐Martín, A., Garrido‐Rodríguez, M., Navarrete, C. M., del Río, C., Bellido, M. L., Appendino, G., Calzado, M. A., & Muñóz, E. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.047 · Cited by 37
Chaturvedi, S., Misra, D. P., Prasad, N., Rastogi, K., Singh, H., Rai, M. K., & Agarwal, V. (2018) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13386 · Cited by 37
T cells and cytokines in systemic sclerosis
Fuschiotti, P. (2018) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000553 · Cited by 38
Genomics of Human Fibrotic Diseases: Disordered Wound Healing Response
Stone, R. C., Chen, V., Burgess, J. L., Pannu, S., & Tomic‐Canic, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228590 · Cited by 40
Romano, E., Rosa, I., Fioretto, B. S., Matucci‐Cerinic, M., & Manetti, M. (2021) · Life · doi:10.3390/life11070610 · Cited by 40
Khanna, D., Denton, C. P., Furst, D. E., Mayes, M. D., Matucci‐Cerinic, M., Smith, V. M., de Vries, D., Ford, P., Bauer, Y., Randall, M. J., et al. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42477 · Cited by 34
A Proteome-Derived Longitudinal Pharmacodynamic Biomarker for Diffuse Systemic Sclerosis Skin
Rice, L. M., Mantero, J. C., Stifano, G., Ziemek, J., Simms, R. W., Gordon, J., Domsic, R. T., & Lafyatis, R. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.08.027 · Cited by 34
Self-citationShowalter, K., Spiera, R., MAGRO, C. M. J., Agius, P., Martyanov, V., Franks, J. M., Sharma, R., Geiger, H. M., Wood, T. A., Zhang, Y., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217840 · Cited by 33
Self-citationIsoform-selective TGF-β3 inhibition for systemic sclerosis
Sun, T., Heiden, J. A. V., Gao, X., Yin, J., Uttarwar, S., Liang, W., Jia, G., Yadav, R., Huang, Z., Mitra, M. S., et al. (2024) · Med · doi:10.1016/j.medj.2023.12.011 · Cited by 36
Use of biologics and other novel therapies for the treatment of systemic sclerosis
Bruni, C., Praino, E., Allanore, Y., Distler, O., Gabrielli, A., Iannone, F., & Matucci‐Cerinic, M. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1263153 · Cited by 31
Reevaluation of Pluripotent Cytokine TGF-β3 in Immunity
Komai, T., Okamura, T., Inoue, M., Yamamoto, K., & Fujio, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082261 · Cited by 34
Bachmann, J. C., Baumgart, S. J., Uryga, A., Bosteen, M. H., Borghetti, G., Nyberg, M., & Herum, K. M. (2022) · Cells · doi:10.3390/cells11101657 · Cited by 31
Leonel, C., Borin, T. F., Ferreira, L. D. C., Moschetta, M. G., Bajgelman, M. C., Viloria‐Petit, A., & Zuccari, D. A. P. D. C. (2017) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-016-9370-7 · Cited by 30
Systemic sclerosis in adults. Part II: management and therapeutics
Jerjen, R., Nikpour, M., Krieg, T. M., Denton, C. P., & Saracino, A. (2022) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.10.066 · Cited by 35
Microvascular significance of TGF-β axis activation in COVID-19
Arguinchona, L., Zagona‐Prizio, C., Joyce, M. E., Chan, E. D., & Maloney, J. P. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1054690 · Cited by 40
Cadherin-11 as a therapeutic target in chronic, inflammatory rheumatic diseases
Sfikakis, P. P., Vlachogiannis, N. I., & CHRISTOPOULOS, P. F. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.01.008 · Cited by 30
Understanding fibrosis in eosinophilic esophagitis: Are we there yet?
Lee, J., Cavender, C. P., Lieberman, P., & Samarasinghe, A. E. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr1017-395r · Cited by 33
Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis?
Clarke, D. L., Murray, L. A., Crestani, B., & Sleeman, M. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.010 · Cited by 33
Autologous Skin Fibroblast‐Based PLGA Nanoparticles for Treating Multiorgan Fibrosis
Long, Q., Liu, Z., Shao, Q., Shi, H., Huang, S., Jiang, C., Qian, B., Zhong, Y., He, X., Xiang, X., et al. (2022) · Advanced Science · doi:10.1002/advs.202200856 · Cited by 30
Treatment of rapidly progressive systemic sclerosis: current and futures perspectives
Mendoza, F. A., Mansoor, M., & Jiménez, S. A. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1114454 · Cited by 33
Corneal fibrosis: From in vitro models to current and upcoming drug and gene medicines
Cubillo, L. T., Gürdal, M., & Zeugolis, D. I. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115317 · Cited by 33
Mehta, H., Goulet, P.-O., Nguyen, V. Q., Pérez, G., Koenig, M., Senécal, J., & Sarfati, M. (2016) · Autoimmunity · doi:10.1080/08916934.2016.1230848 · Cited by 29
Papadimitriou, T. I., van Caam, A., van der Kraan, P. M., & Thurlings, R. M. (2022) · Biomedicines · doi:10.3390/biomedicines10020316 · Cited by 34
Taroni, J., Martyanov, V., Mahoney, J. M., & Whitfield, M. L. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.12.007 · Cited by 30
Self-citationBlockade of TGF-β/Smad signaling by the small compound HPH-15 ameliorates experimental skin fibrosis
Luong, V. H., Chino, T., Oyama, N., Matsushita, T., Sasaki, Y., Ogura, D., Niwa, S., Biswas, T., Hamasaki, A., Fujita, M., et al. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1534-y · Cited by 36
Future Treatment Options in Systemic Sclerosis—Potential Targets and Ongoing Clinical Trials
Bohdziewicz, A., Pawlik, K. K., Maciejewska, M., Sikora, M., Alda-Malicka, R., Czuwara, J., & Rudnicka, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051310 · Cited by 27
The matricellular protein thrombospondin-1 in lung inflammation and injury
Tabary, M., Gheware, A. P., Peñaloza, H. F., & Lee, J. S. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00182.2022 · Cited by 27
Comprehensive Review of Osteogenesis Imperfecta: Current Treatments and Future Innovations
Chaugule, S. R., Constantinou, C. K., John, A. A., Micha, D., Eekhoff, E. M. W., Gravallese, E. M., Gao, G., & Shim, J. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.191 · Cited by 30
Martyanov, V., & Whitfield, M. L. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000237 · Cited by 26
Self-citationNataf, S., Barritault, M., & Pays, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102097 · Cited by 29
The Effects of Anti-TGF-β1 on Epithelial–Mesenchymal Transition in the Pathogenesis of Adenomyosis
Kay, N., Huang, C., Shiu, L., Yu, Y.-C., Chang, Y., Suen, J., Tsai, E., & Huang, S.-T. J. (2020) · Reproductive Sciences · doi:10.1007/s43032-020-00139-0 · Cited by 27
Biomarkers in systemic sclerosis: mechanistic insights into pathogenesis and treatment
Arron, J. R. (2021) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000827 · Cited by 27
Assessment of disease outcome measures in systemic sclerosis
Lafyatis, R., & Valenzi, E. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00803-6 · Cited by 28
Self-citationEmerging therapies for the treatment of systemic sclerosis
Distler, J. H. W., Kuwana, M., Assassi, S., & Denton, C. P. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01294-x · Cited by 29
Hu, D., Jiang, J., Lin, Z., Zhang, C., Moonasar, N., & Qian, S. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.52846 · Cited by 27
Outside in: The matrix as a modifier of muscular dystrophy
Quattrocelli, M., Spencer, M. J., & McNally, E. M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.12.020 · Cited by 27
Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies
Asano, Y., & Varga, J. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.12.007 · Cited by 24
Evaluation and management approaches for scleroderma lung disease
Schoenfeld, S. R., & Castelino, F. V. (2017) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465817713680 · Cited by 28
Guo, J., Yang, T., Zhang, W., Yu, K., Xu, X., Li, W., Song, L., Gu, X., Cao, R., & Cui, S. (2024) · iScience · doi:10.1016/j.isci.2024.108935 · Cited by 28
Shibata, A., Kuno, M., Adachi, R., Sato, Y., Hattori, H., Matsuda, A., Okuzono, Y., Igaki, K., Tominari, Y., Takagi, T., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186587 · Cited by 24
Nataf, S., Guillen, M., & Pays, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235934 · Cited by 24
The Role of Pro-fibrotic Myofibroblasts in Systemic Sclerosis: From Origin to Therapeutic Targeting
Romano, E., Rosa, I., Fioretto, B. S., Matucci‐Cerinic, M., & Manetti, M. (2021) · Current Molecular Medicine · doi:10.2174/0929867328666210325102749 · Cited by 26
Sciurba, J. C., Gieseck, R. L., Jiwrajka, N., White, S. D., Karmele, E. P., Redes, J., Vannella, K. M., Henderson, N. C., Wynn, T. A., & Hart, K. M. (2019) · The Journal of Pathology · doi:10.1002/path.5215 · Cited by 22
Barron, A., Mantero, J. C., Ho, J. D., Nazari, B., Horback, K. L., Bhawan, J., Lafyatis, R., Lam, C. S., & Browning, J. L. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801209 · Cited by 23
Self-citationAn update on biomarker discovery and use in systemic sclerosis
Matsushita, T., & Takehara, K. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1356722 · Cited by 22
Wermuth, P. J., & Jiménez, S. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196559 · Cited by 23
Shifting Shapes: The Endothelial-to-Mesenchymal Transition as a Driver for Cancer Progression
Giordanengo, L., Proment, A., Botta, V., Picca, F., Munir, H., Tao, J., Olivero, M., Taulli, R., Bersani, F., Sangiolo, D., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136353 · Cited by 20
Recent Advances in Treatment of Systemic Sclerosis and Morphea
Teske, N. M., & Fett, N. M. (2023) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00831-2 · Cited by 25
Chemokines in systemic sclerosis
King, J., Abraham, D., & Stratton, R. J. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.12.001 · Cited by 22
Kim, R., & Chang, W. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311724 · Cited by 22
Galant, C., Marchandise, J., Stoenoiu, M. S., Ducreux, J., Groof, A. D., Pirenne, S., den Eynde, B. J. V., Houssiau, F., & Lauwerys, B. R. (2018) · Rheumatology · doi:10.1093/rheumatology/key401 · Cited by 20
Lecarpentier, Y., Schussler, O., CLAES, V. A., & Vallée, A. (2017) · Nuclear Receptor Research · doi:10.11131/2017/101299 · Cited by 21
Is biological therapy in systemic sclerosis the answer?
Misra, D. P., Ahmed, S., & Agarwal, V. (2020) · Rheumatology International · doi:10.1007/s00296-020-04515-6 · Cited by 19
Skin Histology in Systemic Sclerosis: a Relevant Clinical Biomarker
Showalter, K., & Gordon, J. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00970-z · Cited by 19
Self-citationThe uPA System Differentially Alters Fibroblast Fate and Profibrotic Ability in Skin Fibrosis
Zou, M., Teng, Y., Chen, Z., Liu, S., Jia, Y., Zhang, K., Wu, J., Yuan, Z., Tang, X., Yu, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845956 · Cited by 19
Inamo, J. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa447 · Cited by 22
Biomarkers of skin and lung fibrosis in systemic sclerosis
Kaliterna, D. M., & Petrić, M. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1670062 · Cited by 23
Scherer, S. D., Bauer, J., Schmaus, A., Neumaier, C., Herskind, C., Veldwijk, M. R., Wenz, F. K., & Sleeman, J. P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162221 · Cited by 22
Cho, J. S., Fang, T., Reynolds, T. L., Sofia, D. J., Hamann, S., & Burkly, L. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162758 · Cited by 20
Schmidt, K. G., Juan, M. H. S., Trautmann, S., Berninger, L., Schwiebs, A., Ottenlinger, F. M., Thomas, D., Zaucke, F., Pfeilschifter, J. M., & Radeke, H. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01242 · Cited by 20
Immunotherapy of systemic sclerosis
Katsiari, C. G., Simopoulou, T., Alexiou, I., & Sakkas, L. I. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1491508 · Cited by 23
Emerging Roles of Matricellular Proteins in Systemic Sclerosis
Feng, D., & Gerarduzzi, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134776 · Cited by 18
Kreuder, L., Bissey, P.-A., Yip, K. W., & Liu, F. (2025) · International Journal of Radiation Biology · doi:10.1080/09553002.2025.2540353 · Cited by 18
Biomarkers in Scleroderma: Progressing from Association to Clinical Utility
Ligon, C., & Hummers, L. K. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0565-0 · Cited by 18
Controversies: molecular vs. clinical systemic sclerosis classification
Johnson, S. R., Hinchcliff, M., & Asano, Y. (2016) · Journal of Scleroderma and Related Disorders · doi:10.5301/jsrd.5000213 · Cited by 16
Daoussis, D., & Liossis, S. C. (2019) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.30.1.33 · Cited by 18
Breaking the cycle: should we target inflammation, fibrosis, or both?
Baxter, S. K., Irizarry-Caro, R. A., Heiden, J. A. V., & Arron, J. R. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1569501 · Cited by 15
Sawamura, S., Makino, K., Ide, M., Shimada, S., Kajihara, I., Makino, T., Jinnin, M., & Fukushima, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126811 · Cited by 17
Clinical Trial Design Issues in Systemic Sclerosis: an Update
Gordon, J., & Domsic, R. T. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0582-z · Cited by 16
Self-citationChen, W., Wu, S.-Y., Lin, T.-C., Lin, S., & Wu‐Hsieh, B. A. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0161-5 · Cited by 16
Mendoza, F. A., & Jiménez, S. A. (2021) · Rheumatology · doi:10.1093/rheumatology/keab762 · Cited by 16
Metadata
- Authors
- Rice, L. M., Padilla, C. M., McLaughlin, S. R., Mathes, A., Ziemek, J., Goummih, S., Nakerakanti, S., York, M., Farina, G., Whitfield, M. L., Spiera, R. F., Christmann, R. B., Gordon, J. K., Weinberg, J., Simms, R. W., & Lafyatis, R.
- Affiliations
- Boston University (US)
- Hospital for Special Surgery (US)
- Dartmouth College (US)
- Corresponding author
- Lafyatis, Robert
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2015-06-22
- Volume
- 125
- Issue
- 7
- Pages
- 2795-2807
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4563675
- OpenAlex
- W2155049325
- Cited by
- 351
- References
- 53
- Citations by year
- 2026: 19 · 2025: 26 · 2024: 30 · 2023: 27 · 2022: 37 · 2021: 30 · 2020: 28 · 2019: 24 · 2018: 42 · 2017: 41 · 2016: 34 · 2015: 13
- FWCI
- 34.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Scleroderma Research Foundation
- Bristol-Myers Squibb
- GlaxoSmithKline
- Gilead Sciences
- Alexion Pharmaceuticals
- Celgene
- United Therapeutics Corporation
- Dr. Ralph and Marian Falk Medical Research Trust
- Hospital for Special Surgery
- Cytori Therapeutics
- National Institutes of Health
- Genentech
- Clinical and Translational Science Institute, Boston University
- National Cancer Institute (P30CA023108)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR051089, R03AR062721, P30AR061271, P50AR060780)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Health Sciences › Medicine › Rheumatology › Dupuytren's Contracture and Treatments
- Keywords
- systemic sclerosis, diffuse cutaneous systemic sclerosis, TGF-beta inhibition, skin fibrosis, thrombospondin-1, cartilage oligomeric matrix protein, myofibroblasts, connective tissue growth factor, SERPINE1, modified Rodnan skin score, pharmacodynamic biomarkers, neutralizing antibodies
- MeSH terms
- Adult, Antibodies, Monoclonal, Female, Genetic Markers, Humans, Male, Middle Aged, Scleroderma, Systemic, Gene Expression, Transforming Growth Factor beta, Treatment Outcome, Thrombospondin 1, Myofibroblasts, Antibodies, Monoclonal, Humanized, Cartilage Oligomeric Matrix Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.